^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD25hi Treg depleted DLI

    i
    Other names: CD25hi Treg depleted DLI
    Associations

    News

    Trials
    Company:
    Dana-Farber Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jul 2024 --> Jul 2025
    Trial completion date
    |
    IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Yervoy (ipilimumab) • CD25hi Treg depleted DLI
    5ms
    A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jul 2024
    Enrollment closed • Trial completion date
    |
    IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Yervoy (ipilimumab) • CD25hi Treg depleted DLI
    over1year
    A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (clinicaltrials.gov)
    P1, N=25, Recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2023 --> May 2024
    Trial completion date • Trial primary completion date
    |
    IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Yervoy (ipilimumab) • CD25hi Treg depleted DLI
    over2years
    A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (clinicaltrials.gov)
    P1, N=25, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Apr 2022 --> May 2023
    Trial primary completion date
    |
    IL2RA (Interleukin 2 receptor, alpha)
    |
    Yervoy (ipilimumab) • CD25hi Treg depleted DLI